Louise Chen
Stock Analyst at Scotiabank
(3.23)
# 1,067
Out of 5,050 analysts
296
Total ratings
45.99%
Success rate
1.65%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $17.63 | +353.77% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $2.32 | +287.93% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $17.17 | -18.46% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.96 | +512.24% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $20.86 | +163.66% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $71.76 | -23.36% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $2.19 | +584.93% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $77.83 | -35.76% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $5.59 | +168.34% | 5 | Mar 7, 2025 | |
| COGT Cogent Biosciences | Initiates: Sector Outperform | $17 | $14.82 | +14.71% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $69.84 | +0.23% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $18.36 | +172.33% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $8.85 | +238.98% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $21.90 | +151.14% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.46 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $45.68 | +250.26% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $41.65 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $219.16 | +9.51% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $24.43 | +84.20% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $186.57 | +15.24% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.81 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $86.28 | +79.65% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $20.62 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $924.37 | -4.26% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.56 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $23.35 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $14.61 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.61 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $104.39 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.82 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.55 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.71 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.91 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $657.53 | +40.68% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.60 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.17 | +1,950.47% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.55 | +222.58% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $14.95 | +234.45% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $24.23 | +106.36% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.39 | +259.71% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.35 | +2,454.64% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $1.78 | +94,803,270.79% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $262.60 | -1.75% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $23.97 | -37.42% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.10 | +4,445.45% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.34 | +1,392.54% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $9.11 | +393.96% | 1 | Jun 22, 2017 |
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $17.63
Upside: +353.77%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $2.32
Upside: +287.93%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $17.17
Upside: -18.46%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.96
Upside: +512.24%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $20.86
Upside: +163.66%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $71.76
Upside: -23.36%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $2.19
Upside: +584.93%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $77.83
Upside: -35.76%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.59
Upside: +168.34%
Cogent Biosciences
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $14.82
Upside: +14.71%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $69.84
Upside: +0.23%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $18.36
Upside: +172.33%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $8.85
Upside: +238.98%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $21.90
Upside: +151.14%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.46
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $45.68
Upside: +250.26%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $41.65
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $219.16
Upside: +9.51%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $24.43
Upside: +84.20%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $186.57
Upside: +15.24%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.81
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $86.28
Upside: +79.65%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.62
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $924.37
Upside: -4.26%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.56
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $23.35
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $14.61
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.61
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $104.39
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.82
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.55
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.71
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.91
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $657.53
Upside: +40.68%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.60
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.17
Upside: +1,950.47%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $1.55
Upside: +222.58%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $14.95
Upside: +234.45%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $24.23
Upside: +106.36%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.39
Upside: +259.71%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.35
Upside: +2,454.64%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $1.78
Upside: +94,803,270.79%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $262.60
Upside: -1.75%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $23.97
Upside: -37.42%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.10
Upside: +4,445.45%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.34
Upside: +1,392.54%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $9.11
Upside: +393.96%